Topical eye drops continue to face hurdles

NEW ORLEANS — According to one speaker, topical eye drops have disadvantages: ocular surface toxicity, burden of cost and issues of patient adherence with triple therapy. Compounded combination therapies are a new way to address those disadvantages perioperatively, Damien Goldberg, MD, said during Cornea Day preceding the American Society of Cataract and Refractive Surgery meeting.“The biggest challenge we find is that the FDA won’t let us do the simplest thing: put all three in one bottle,” he said.